Johnson & Johnson (JNJ)vsScinai Immunotherapeutics Ltd (SCNI)
JNJ
Johnson & Johnson
$229.85
+1.10%
HEALTHCARE · Cap: $547.28B
SCNI
Scinai Immunotherapeutics Ltd
$0.74
+3.67%
HEALTHCARE · Cap: $2.06M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 7350167% more annual revenue ($96.36B vs $1.31M). JNJ leads profitability with a 21.8% profit margin vs 0.0%. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
SCNI
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-43.5%
Fair Value
$160.13
Current Price
$229.85
$69.72 premium
Margin of Safety
+52.8%
Fair Value
$1.59
Current Price
$0.74
$0.85 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Reasonable price relative to book value
Revenue surging 30.6% year-over-year
Earnings expanding 87.2% YoY
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
ROE of -91.9% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : SCNI
The strongest argument for SCNI centers on Price/Book, Revenue Growth, EPS Growth. Revenue growth of 30.6% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : SCNI
The primary concerns for SCNI are Market Cap, Profit Margin, Piotroski F-Score.
Key Dynamics to Monitor
JNJ profiles as a mature stock while SCNI is a hypergrowth play — different risk/reward profiles.
SCNI carries more volatility with a beta of 1.99 — expect wider price swings.
SCNI is growing revenue faster at 30.6% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 48/100), backed by strong 21.8% margins. SCNI offers better value entry with a 52.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Scinai Immunotherapeutics Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Scinai Immunotherapeutics Ltd is a cutting-edge biotechnology company specializing in the development of innovative immunotherapy solutions aimed at treating cancer and autoimmune disorders. Utilizing its proprietary immune modulation platform, Scinai is advancing a robust clinical pipeline that focuses on delivering transformative therapies to improve patient outcomes. With a highly experienced leadership team and a commitment to rigorous research, the company is well-positioned to capitalize on the growing demand for advanced immunotherapeutics in the global healthcare landscape. Strategic partnerships further enhance Scinai's potential for significant growth, establishing it as a key player in the biopharmaceutical sector.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?